Major depressive disorder
Drug research and approvals for major depressive disorder: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 476 studies of major depressive disorder are recruiting on ClinicalTrials.gov, Health Canada has authorized 62 drug trials for it since 2013, and the EU has 4 authorised medicines for it.
- Recruiting worldwide: 476
- Trials authorized in Canada: 62
- FDA orphan approvals: 0
- EU medicines: 4
Recruiting Now
Newest start dates first, of 476 recruiting on ClinicalTrials.gov ↗- Mechanisms of Repeated Real-time Biofeedback With 7-Tesla MRI in DepressionNCT07694076 · Not applicable · University of Oxford · starts Dec 1, 2026
- PROMOTE: Effects of 5-HT4 Agonism on Cognition and Sleep in Peopl With Low MoodNCT07848477 · Not applicable · University of Oxford · starts Nov 10, 2026
- Longitudinal Assessment of Biomarkers Among Patients With MDDNCT07931001 · Not reported · Massachusetts General Hospital · starts Nov 5, 2026
- Functional Magnetic Resonance Imaging Study of Inhibitory Control in Bipolar Disorder and Major Depressive DisorderNCT07503275 · Not applicable · CHU de Reims · starts Nov 3, 2026
- Emotional Reactivity in Severe Alcohol Use Disorder and Major Depressive Disorder Using Eye-tracking, Physiological,…NCT07925281 · Not reported · Université Catholique de Louvain · starts Nov 2, 2026
- EEG-Guided Transcranial Magnetic Stimulation for Adults With DepressionNCT07862205 · Not applicable · Mayo Clinic · starts Nov 2, 2026
- A Mechanistic Study to Assess a Single Dose of CYB003 in Participants With Depression and AnxietyNCT06820723 · Phase 2 · Ohio State University · starts Nov 1, 2026
- Mobile Cognitive Behavioral Therapy in Early Stroke RecoveryNCT07639606 · Not applicable · Weill Medical College of Cornell University · starts Nov 1, 2026
- Neuromodulation of Motivation and Reward OscillationsNCT07924852 · Not applicable · Florida State University · starts Nov 1, 2026
- Cortical rTMS as a Treatment for DepressionNCT05487911 · Not applicable · Baylor College of Medicine · starts Nov 1, 2026
Trials Authorized in Canada
The 10 newest of 62; search them all in Canada trials| Sep 28, 2026 | A phase 2, multicenter, double-blind, randomized, placebo-controlled, parallel-group study with an open-label treatment period to evaluate the efficacy and…AGN-151607-DP (GEMIBOTULINUMTOXINA) | AbbVie | Pending |
| Sep 10, 2026 | A comparative analysis of the pharmacokinetics of oral and sublingual ketamine as adjunctive therapies in major depressive disorderKETAMINE | DR. ROHIT LODHI | Pending |
| Sep 8, 2026 | A phase 3, multicenter, randomized, double-blind, parallel-arm study to investigate the efficacy and safety of adjunctive treatment with brenipatide in…BRENIPATIDE (LY3537031) | Eli Lilly | Ongoing |
| Jun 11, 2026 | A phase 3, multicenter, randomized, double-blind, parallel-arm study to investigate the efficacy and safety of adjunctive treatment with brenipatide in…BRENIPATIDE (LY3537031) | Eli Lilly | Ongoing |
| Jun 11, 2026 | Optimizing the synergy between behavioural activation therapy and intravenous ketamine for treatment resistant depressionKETAMINE | UNIVERSITY OF OTTAWA INSTITUTE OF MENTAL HEALTH RESEARCH | Pending |
| May 29, 2026 | A multicenter, double-blind, randomized, placebo-controlled study to evaluate efficacy and safety of seltorexant as monotherapy in adult and elderly…SELTOREXANT (JNJ-42847922) | Johnson & Johnson | Ongoing |
| Nov 26, 2025 | Psilocybin-assisted psychotherapy for major depressive disorder in women with a history of childhood maltreatment: a pilot trialPSILOCYBIN (PEX010) | DR. ELISA BRIETZKE | Ongoing |
| Nov 6, 2025 | Sustained mood improvement with laughing gas exposure: a randomized controlled double-blind trialNITROUS OXIDE / MIDAZOLAM | WOMENS COLLEGE HOSPITAL | Pending |
| Sep 26, 2025 | 18f]bcpp-ef pet imaging of mitochondrial complex i in major depressive disorder, treatment-resistant major depressive disorder, and long covid (pasc)[18F]BCPP-EF | CENTRE FOR ADDICTION AND MENTAL HEALTH | Ongoing |
| Aug 19, 2025 | Two-week, open-label, exploratory neuroimaging study evaluating the effect of dextromethorphan-hbr bupropion-hcl on striatal reactivity during reward…DEXTROMETHORPHAN-BUPROPION | BRAIN AND COGNITION DISCOVERY FOUNDATION | Pending |
Medicines Authorised in the EU
Newest first| Dec 18, 2019 | Spravatoesketamine | Janssen-Cilag International NV | EMA ↗ |
| Jun 19, 2015 | Duloxetine Viatris (previously Duloxetine Mylan)duloxetine · generic | Viatris Limited | EMA ↗ |
| Dec 8, 2014 | Duloxetine Lillyduloxetine | Eli Lilly Nederland B.V. | EMA ↗ |
| Dec 17, 2004 | Cymbaltaduloxetine | Eli Lilly Nederland B.V. | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA